The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

The massive pharmacy benefit manager plans to stop requiring coverage authorizations for roughly 80 drugs used to treat ...

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company ...

Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.

Pfizer PFE1.28%increase; green up pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.

Healthcare companies rose as traders sought out sectors that are less vulnerable to swings in economic growth and inflation prospects.

Taiwan Semiconductor Manufacturing, Salesforce, Oracle, Exxon Mobil, ServiceNow, D-Wave Quantum, and Pfizer are the seven Manufacturing stocks to watch today, according to MarketBeat’s stock screener ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

and made an $11.6 billion takeover bid for Biohaven and its migraine therapy Nurtec ODT (rimegepant).